About the Safety Working Group

Harms provide important context for healthcare practitioners about the benefit-risk ratio of interventions. To improve transparency and credibility in the published results from randomized trials, the reporting of harms associated with an intervention needs to be explicit regarding what is patient-important, which may be different from that reported by clinicians submitting adverse event reports

Following the concerns about inadequate reporting of harm outcomes in randomized trials and systematic reviews the Outcome Measures in Rheumatology (OMERACT) Safety Working Group is advancing the work to identify additional harm aspects for assessment in rheumatology trials

Peter Brooks

Peter Brooks

Co-Chair

Robin Christensen

Robin Christensen

Co-Chair

Lee Simon

Lee Simon

Co-Chair

Dorthe B. Berthelsen

Fellow

amye leong

Amye Leong

Patient Research Partner

Marieke Scholte-Voshaar

Marieke Scholte-Voshaar

Patient Research Partner

Working Group Members:

Maarten Boers
Peter Brooks
Robin Christensen
Daniel Devoe
Daniel Furst
Niti Goel
Susan Goodman
Glen Hazelwood
Orit Schieir
Vivian Bykerk

Catherine Hill
Louise Klokker
Amye Leong
Sarah Mackie
Pam Richards
Marieke Scholte-Voshaar
Lee Simon
Dorthe Berthelsen
Caroline Flurey
Dorcas Beaton

Vibeke Strand
Maria Suarez-Almazor
Caroline Terwee
Peter Tugwell
Paula Williamson
Thasia Woodworth
David Henry

Scroll to Top